Navigation Links
Strativa Pharmaceuticals Signs Agreement With Swedish Orphan Biovitrum Regarding Nascobal®
Date:10/26/2010

ts" within the meaning of the Private Securities Litigation Reform Act of 1995.  To the extent any statements made in this news release contain information that is not historical, these statements are essentially forward-looking and, as such, are subject to known and unknown risks, uncertainties and contingencies, many of which are beyond the control of the Company, which could cause actual results and outcomes to differ materially from those expressed herein.  Risk factors that might affect such forward-looking statements include those set forth in Item 1A of the Company's most recent Annual Report on Form 10-K, in other of the Company's filings with the SEC from time to time, including Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, and on general industry and economic conditions.  Any forward-looking statements included in this news release are made as of the date hereof only, based on information available to the Company as of the date hereof, and, subject to any applicable law to the contrary, the Company assumes no obligation to update any forward-looking statements.


'/>"/>
SOURCE Strativa Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. FDA Approves Strativa Pharmaceuticals Zuplenz® (ondansetron) Oral Soluble Film
2. Strativa Pharmaceuticals Provides An Update On Zuplenz(R) (Ondansetron) Oral Soluble Film
3. Strativa Pharmaceuticals Development Partner, BioAlliance Pharma, Presents Phase III Study Results of Miconazole Lauriad(R) for the Treatment of Oropharyngeal Candidiasis
4. Strativa Pharmaceuticals Provides Product Pipeline Update
5. Strativa Pharmaceuticals Announces Preliminary Results from ONCONASE(R) Phase IIIb Clinical Trial
6. Strativa Pharmaceuticals Announces Phase III Results for Loramyc(R) to Treat Oropharyngeal Candidiasis
7. Keryx Biopharmaceuticals Announces Completion of Patient Enrollment In Zerenex Phase 3 Short-Term Study
8. Celtic Therapeutics and Resolvyx Pharmaceuticals Announce an Alliance in Ophthalmology
9. Savient Pharmaceuticals to Hold Conference Call on October 26, 2010 at 8:30 a.m. Eastern Time
10. Savient Pharmaceuticals Provides Update on Strategic Alternatives Process
11. Optimer Pharmaceuticals Announces Combined Data From Fidaxomicin Phase 3 Trials for the Treatment of Clostridium difficile Infection (CDI) Presented at IDSA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... RAPIDS, Mich. , Jan. 15, 2014 As health ... the flu virus, select Meijer pharmacies in Michigan ... strep throat to eligible patients, enabling Meijer pharmacists to administer ... strict protocol set by a physician participating in the study. ...
(Date:1/15/2014)...  Celsion Corporation (the "Company") (NASDAQ: CLSN ) ... investors to purchase an aggregate of approximately $15 million ... direct offering, led by a dedicated health care fund. ... with these investors pursuant to which the Company agreed ...
(Date:1/15/2014)... Texas , Jan. 15, 2014  Humberto C. Antunes,  ... Achievement Award" from the Journal of Drugs in ... & Clinical Conference (ODAC). The event is January 17-20, 2014, at ... Florida . The ODAC is ...
Breaking Medicine Technology:Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 2Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 3Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4
(Date:4/18/2014)... University psychologists have made a brain-related discovery that ... disorders. , This discovery opens up the possibility ... suppress a specific brain activity that the researchers ... The Journal of Neuroscience has just ... McDonald, an associate professor of psychology and his ...
(Date:4/17/2014)... non-cancerous prostate tissue may have nearly twice the risk ... inflammation, according to results of a new study led ... , The link between persistent inflammation and cancer was ... those with a Gleason score between 7 and ... and rapidly growing prostate cancers. , "What we,ve shown ...
(Date:4/17/2014)... April issue of Experimental Biology and Medicine ... Rex Gaskins and Paul Kenis in the Institute ... the University of Illinois Urbana-Champaign describe their recent ... underlie a variety of cell functions including energy ... crucial roles in regulating normal cellular behavior, redox ...
(Date:4/17/2014)... A Northwestern University synthetic biology team has created ... create programmable therapeutics that could travel the body ... disease. , Engineering cell-based, biological devices that monitor ... in clinical synthetic biology. However, no existing technology ... a patient,s physiological state and respond in a ...
(Date:4/17/2014)... IL, April 17, 2014-- Colic affects about one in ... for numerous pediatric visits during the first several months ... colic symptoms was showing promise; however, the April 1, ... (BMJ2014;348:g2107; Sung, Valerie) reported on a study, "Probiotics and ... L reuteri for infant colic did ...
Breaking Medicine News(10 mins):Health News:Scientists discover brain's anti-distraction system 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 3Health News:Live cell imaging reveals distinct alterations of subcellular glutathione potentials 2Health News:Building 'smart' cell-based therapies 2Health News:New study says probiotic use for infant colic is not effective in reducing symptoms 2
... five times more lethal than other strains and has shown ... used to treat MRSA, according to a Henry Ford Hospital ... patients infected with the strain died within 30 days compared ... The average 30-day mortality rate for MRSA bloodstream ...
... receive a kidney transplant rarely develop the serious inflammatory ... a paper being presented at the American Society of ... Diego, CA. The findings indicate that having lupus should ... they need one. Individuals with the autoimmune disease ...
... A Henry Ford Hospital study found that hepatitis B does not ... is a contributing factor. The results contradict a previous ... previous hepatitis B infection. Hepatitis B is an inflammation of the ... presented at the American Association for the Study of Liver Diseases, ...
... ... Ontario health care professionals will hear firsthand from some of the ... in North America at an international conference on the diagnosis and treatment ... in the vitamin D field are presenting information that looks at the ...
... Amgen (Nasdaq: AMGN ) today announced the ... Cardiovascular Events with Aranesp® Therapy), a large, randomized, double-blind, ... kidney disease (CKD) not on dialysis, moderate anemia and ... New England Journal of Medicine and presented ...
... Oct. 30 Today Company C announced it will ... Komen for the Cure®. , On Saturday and Sunday, ... Passion for Pink event, during which 15 percent of all ... and local breast cancer awareness, research and education. A New ...
Cached Medicine News:Health News:Henry Ford Hospital study: A MRSA strain linked to high death rates 2Health News:Kidney transplants generally safe for lupus patients 2Health News:Toronto Conference Targets the Vitamin D Deficiency Crisis 2Health News:Toronto Conference Targets the Vitamin D Deficiency Crisis 3Health News:Large Study of Anemia Treatment in Chronic Kidney Disease Patients Not on Dialysis Published in the New England Journal of Medicine Failed to Meet Primary Efficacy Endpoints 2Health News:Large Study of Anemia Treatment in Chronic Kidney Disease Patients Not on Dialysis Published in the New England Journal of Medicine Failed to Meet Primary Efficacy Endpoints 3Health News:Large Study of Anemia Treatment in Chronic Kidney Disease Patients Not on Dialysis Published in the New England Journal of Medicine Failed to Meet Primary Efficacy Endpoints 4Health News:Large Study of Anemia Treatment in Chronic Kidney Disease Patients Not on Dialysis Published in the New England Journal of Medicine Failed to Meet Primary Efficacy Endpoints 5Health News:Large Study of Anemia Treatment in Chronic Kidney Disease Patients Not on Dialysis Published in the New England Journal of Medicine Failed to Meet Primary Efficacy Endpoints 6Health News:Large Study of Anemia Treatment in Chronic Kidney Disease Patients Not on Dialysis Published in the New England Journal of Medicine Failed to Meet Primary Efficacy Endpoints 7Health News:Large Study of Anemia Treatment in Chronic Kidney Disease Patients Not on Dialysis Published in the New England Journal of Medicine Failed to Meet Primary Efficacy Endpoints 8Health News:Large Study of Anemia Treatment in Chronic Kidney Disease Patients Not on Dialysis Published in the New England Journal of Medicine Failed to Meet Primary Efficacy Endpoints 9Health News:Company C Donates $40,000 To Fight Breast Cancer 2
... The Dimension Vista 1500 ... turbidemetry, nephelometry, IMT (integrated multisensor ... new design will integrate analysis ... chemistries, drugs-of-abuse, therapeutic drugs, immunosuppressive ...
... high performance portable ultrasound design provides ... echocardiography. Echocardiography (ultrasound) imaging requires ... and sensitive Doppler performance. The ... Terason's proprietary Teratech Architecture, delivers a ...
... passes through the GI tract, it transmits data ... the SmartPill Data Receiver, a small, light-weight, battery ... (supported by either a belt or lanyard). The ... measurement data, and elapsed and real time. After ...
... Endoscopic cases it is extremely popular to combine ... Light. This combination affords the surgeon optimal ... an uncomfortable pose. The Dual Light System ... System. As such the light can be ...
Medicine Products: